# US 2008/0188447 A1 · Glucocorticoid-lowering composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188447 A1
- Document ID: US20080188447A1
- Status: Published application
- Kind: A1
- Application number: 12/011,246
- Filed: 2008-01-25
- Published: 2008-08-07
- Earliest claimed: 2007-02-02
- Inventors: Svyatoslav Komarnytsky; Dmitry Govorko; Joseph M. O'Neal; Ilya Raskin
- Web page: https://patentgrep.com/patent/US20080188447A1

## CPC

- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 5/00: Drugs for disorders of the endocrine system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to a composition comprising pregnane derivatives according to Formula (I), or a salt, solvate or hydrate thereof, and to a pharmaceutically acceptable carrier or excipient. The composition may be used to lower glucocorticoid level in a human or animal. It may also be used tor modulate activity of enzymes of glucocorticoid metabolism, to modulate RNA transcription and protein level of hypothalamic, hippocampal and pituitary peptides, or for treatment or prophylaxis of human or animal diseases.

## Claims

### Claim 1

A therapeutic method comprising administering to a subject who has a higher than normal glucocorticoid level a composition comprising a pregnane derivative according to Formula (I) or a salt, solvate or hydrate thereof, wherein said composition lowers the circulating glucocorticoid level.

### Claim 2 (depends on 1)

The method of claim 1 wherein the therapy is for an endocrinal or metabolic-related disorder that is a hormonal imbalance or a defect in central energy regulation or central energy expenditure.

### Claim 3 (depends on 2)

The method of claim 2 wherein the therapy is for Cushing's syndrome.

### Claim 4 (depends on 1)

The method of claim 1 wherein the therapy is a treatment for a neural-associated disorder.

### Claim 5 (depends on 1)

The method of claim 1 wherein the therapy is for a chronic stress disorder and the composition alleviates stress.

### Claim 6 (depends on 1)

The method of claim 1 wherein the therapeutic method is for a human or veterinary therapy.

### Claim 7

A method of prophylaxis for a defect in central energy regulation or expenditure comprising administering to a subject a composition comprising a pregnane derivative according to Formula (I) or a salt, solvate or hydrate thereof, wherein said composition modifies the metabolism to decrease energy expenditure.

### Claim 8

A method for modulating the activity of a factor or enzyme of glucocorticoid metabolism comprising contacting the factor or enzyme with a pregnane derivative according to Formula (I) or a salt, solvate or hydrate thereof.

### Claim 9 (depends on 8)

The method of claim 8 wherein the contacting is in vivo.

### Claim 10 (depends on 8)

The method of claim 8 wherein the contacting is in vitro.

### Claim 11 (depends on 8)

The method of claim 8 wherein the factor or enzyme is CYP11A1 or HSD3B2.

### Claim 12

A method for modulating RNA transcription of a hypothalamic, hippocampal or pituitary peptide comprising contacting a hypothalamic, hippocampal or pituitary cell with a pregnane derivative according to Formula (I) or a salt, solvate or hydrate thereof.

### Claim 13 (depends on 12)

The method of claim 12 wherein the contacting is in Vivo.

### Claim 14 (depends on 12)

The method of claim 12 wherein the contacting is in vitro.

### Claim 15 (depends on 12)

The method of claim 12 wherein the peptide is CRH.

### Claim 16

A method for modulating the level of a hypothalamic, hippocampal or pituitary peptide comprising contacting a hypothalamic, hippocampal or pituitary cell with a pregnane derivative according to Formula (I) or a salt, solvate or hydrate thereof.

### Claim 17 (depends on 16)

The method of claim 16 wherein the contacting is in vivo.

### Claim 18 (depends on 16)

The method of claim 16 wherein the contacting is in vitro.

### Claim 19 (depends on 16)

The method of claim 16 wherein the peptide is CRH.